Literature DB >> 2874986

Comparative study in mice of ten 1,4-benzodiazepines and of clobazam: anticonvulsant, anxiolytic, sedative, and myorelaxant effects.

L Stéru, R Chermat, B Millet, J A Mico, P Simon.   

Abstract

We will present data from the comparison between four tests in mice of 10 1,4-benzodiazepines and one 1,5-benzodiazepine (clobazam). The tests used were: the "4 plates test" of anxiolytic activity; the electroshock test to determine the anticonvulsive effects; actimetry to predict the sedative effect on motricity; and traction test to predict the myorelaxant effect. The latter two tests have been suggested to be predictive of side-effects that damage psychomotor efficiency in human patients. A comparison of ED50s determined from the predictive tests of the therapeutic effect and those of the side-effects led to the calculation of ratios considered to be predictive of the safety margin. A classification according to this margin shows the advantages of the 1,5-benzodiazepine compared with the 1,4-benzodiazepines. Despite the caution needed in the extrapolation of the results from animals to humans, this work stresses the interesting place that the 1,5-benzodiazepine seem to hold as anticonvulsant in clinical practice.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2874986     DOI: 10.1111/j.1528-1157.1986.tb05728.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  11 in total

Review 1.  GABA(A) receptor physiology and its relationship to the mechanism of action of the 1,5-benzodiazepine clobazam.

Authors:  Raman Sankar
Journal:  CNS Drugs       Date:  2012-03-01       Impact factor: 5.749

2.  Differential effects of six structurally related benzodiazepines on some ethological measures of timidity, aggression and locomotion in mice.

Authors:  M Krsiak; A Sulcova
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 3.  Experience in the use of clobazam in the treatment of Lennox-Gastaut syndrome.

Authors:  Gabriela Purcarin; Yu-Tze Ng
Journal:  Ther Adv Neurol Disord       Date:  2014-05       Impact factor: 6.570

4.  Intermittent clobazam therapy in febrile seizures.

Authors:  Winsley Rose; Chellam Kirubakaran; Julius Xavier Scott
Journal:  Indian J Pediatr       Date:  2005-01       Impact factor: 1.967

5.  Comparison of several benzodiazepine receptor ligands in two models of anxiolytic activity in the mouse: an analysis based on fractional receptor occupancies.

Authors:  G H Jones; C Schneider; H H Schneider; J Seidler; B J Cole; D N Stephens
Journal:  Psychopharmacology (Berl)       Date:  1994-03       Impact factor: 4.530

Review 6.  Elucidating the mechanism of action of pregabalin: α(2)δ as a therapeutic target in anxiety.

Authors:  Juan-Antonio Micó; Rita Prieto
Journal:  CNS Drugs       Date:  2012-08-01       Impact factor: 6.497

7.  Synthesis and anticonvulsant activity of various mannich and schiff bases of 1,5-benzodiazepines.

Authors:  Surendra N Pandeya; Neha Rajput
Journal:  Int J Med Chem       Date:  2012-11-28

8.  Functional characterization of the 1,5-benzodiazepine clobazam and its major active metabolite N-desmethylclobazam at human GABA(A) receptors expressed in Xenopus laevis oocytes.

Authors:  Harriet Hammer; Bjarke Ebert; Henrik Sindal Jensen; Anders A Jensen
Journal:  PLoS One       Date:  2015-03-23       Impact factor: 3.240

9.  Clinical considerations in transitioning patients with epilepsy from clonazepam to clobazam: a case series.

Authors:  Raman Sankar; Steve Chung; Michael Scott Perry; Ruben Kuzniecky; Saurabh Sinha
Journal:  J Med Case Rep       Date:  2014-12-16

10.  Clobazam and its active metabolite N-desmethylclobazam display significantly greater affinities for α₂- versus α₁-GABA(A)-receptor complexes.

Authors:  Henrik Sindal Jensen; Kathryn Nichol; Deborah Lee; Bjarke Ebert
Journal:  PLoS One       Date:  2014-02-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.